Tenax Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tenax Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 32,413% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Tenax Therapeutics, Inc. made a loss over the last year. Tenax Therapeutics, Inc. owes $0.07 for every $1 it owns. Tenax Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTenax Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.58The share price is 0.58 times Tenax Therapeutics, Inc.'s book value per share, lower than 89% of Healthcare companies in United States.
Market cap
$66 MThe total market value of all of Tenax Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$114 MWhat Tenax Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.04Net worth divided by the number of shares. The share price of $1.76 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-59.8%Tenax Therapeutics, Inc. lost 59.8% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
Owes vs Owns
0.07×Tenax Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Dividend yield
NoneTenax Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossTenax Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tenax Therapeutics, Inc.: $66 M ÷ $114 M (30 Jun 2026) = 0.6.
What is Tenax Therapeutics, Inc.'s return on equity?
Tenax Therapeutics, Inc. lost 59.8% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
How much does Tenax Therapeutics, Inc. owe compared with what it owns?
Tenax Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Does Tenax Therapeutics, Inc. pay a dividend?
No. Tenax Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.